Home > Insider Trading > Filing (0000899243-20-022200)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1651431	Checkmate Pharmaceuticals Inc.	CMPI	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1202793	Michael Powell	C/O Sofinnova Investments, Inc. 3000 Sand Hill Road, Bldg. 4, Suite 250 Menlo Park CA 94025	Yes	No	Yes	No
1245624	James Healy	C/O Sofinnova Investments, Inc. 3000 Sand Hill Road, Bldg. 4, Suite 250 Menlo Park CA 94025	No	No	Yes	No
1612133	Sofinnova Venture Partners Ix, L.p.	C/O Sofinnova Investments, Inc. 3000 Sand Hill Road, Bldg. 4, Suite 250 Menlo Park CA 94025	No	No	Yes	No
1612134	Sofinnova Management Ix, L.l.c.	C/O Sofinnova Investments, Inc. 3000 Sand Hill Road, Bldg. 4, Suite 250 Menlo Park CA 94025	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-08-11	3,473,374	$0.00	3,473,374	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2020-08-11	133,333	$15.00	3,606,707	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2020-08-11	12,500,000	$0.00	1,671,771	$0.00
Common Stock	Series B Preferred Stock	Disposition	2020-08-11	8,753,350	$0.00	1,314,165	$0.00
Common Stock	Series C Preferred Stock	Disposition	2020-08-11	3,644,624	$0.00	487,438	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
The Series B Preferred Stock automatically converted into Common Stock at a rate of 1.12256:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
The securities are held directly by Sofinnova Venture Partners IX, L.P. (the "Fund"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the "GP") and may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Fund. Dr. James I. Healy and Michael F. Powell, Ph.D. are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by the Fund. Each reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein, if any.